1h Free Analyst Time
The non-small cell lung cancer drugs market is forecasted to grow by USD 15936.89 mn during 2022-2027, accelerating at a CAGR of 9.25% during the forecast period. The report on the non-small cell lung cancer drugs market provides a holistic analysis, market size, and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence and incidence of non-small cell lung cancer, the strong drug pipeline and recent drug approvals, and the availability of patient assistance programs.
The non-small cell lung cancer drugs market is segmented as below:
By Type
- Adenocarcinoma
- Squamous cell carcinoma
- Large cell carcinoma
By Product
- Biologics
- Small molecule targeted therapy
- Chemotherapy
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the non-small cell lung cancer drugs market covers the following areas:
- Non-small cell lung cancer drugs market sizing
- Non-small cell lung cancer drugs market forecast
- Non-small cell lung cancer drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global non-small cell lung cancer drugs market: AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., PharmaMar SA, Regeneron Pharmaceuticals Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is an introduction and approval of combination therapies.'
According to the report, one of the major drivers for this market is the increasing prevalence and incidence of non-small cell lung cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bayer AG
- BeiGene Ltd.
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Innovent Biologics Inc.
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.
- Merck KGaA
- Novartis AG
- Ono Pharmaceutical Co. Ltd.
- Pfizer Inc.
- PharmaMar SA
- Regeneron Pharmaceuticals Inc.
- Sanofi
- Takeda Pharmaceutical Co. Ltd.
